JSW Dulux Limited (JSWDULUX)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 volume growth 21.8%, revenue growth 21.3%, EBITDA INR110.9 Cr +4.4% y-y
- Industrial business grew 32%+, decorative mid-double-digit volume growth; industrial margins pressured by raw material inflation
- Price hikes: 7.9% average in quarter, 10.4% exit; industrial price recovery lagging but underway
- Project Akshaya synergy savings INR7.3 Cr in Q2; target 7-10% EBITDA improvement annually
- Capex focused on industrial capacity and decorative tinting/store expansion
- Competitive intensity remains high with pricing discipline improving
- Tax rate Q2 low due to one-off favorable order; full year expected ~25%
- Working capital elevated due to titanium dioxide prebuy; normalization expected in 3-5 months
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 JSWDULUX — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add JSWDULUX to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on JSW Dulux Limited
Important.
The summary above is generated automatically from JSW Dulux Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.